Given the oncogenic role played by NRF2 in osteosarcoma, and its degradation by ubiquitination, here proposed as a possible osteosarcoma therapy, the activity of DUBs, able to remove the ubiquitin chains from NRF2, represents a serious obstacle for the development of a therapeutic approach. Here, NFE2L2 is linked to osteosarcoma.